Track the Swedish Orphan Biovitrum AB (publ) stock price and the full directors' dealings record of the company, a publicly traded company based in Finland. Shares are listed on the FI market, under the supervision of FIN-FSA. Operating in the Health Care sector, Swedish Orphan Biovitrum AB (publ) has recorded 69 public disclosures. Market capitalisation: €153.6bn. The latest transaction was disclosed on 17 August 2026 (Purchase). Among the most active insiders: Guido Oelkers. The full history is openly available.
69
Insider Decl.
n/a
Thresholds
€34m
47 ops.
Buy Volume
€44m
22 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Swedish Orphan Biovitrum AB (publ) Buy (bullish), based on 12 analysts. Average price target: SEK 497.58.
32Σ signal
Buys €34m€44m Sells
Fundamental score
Ranked 15,816 of 29,055 companies
49.6
score / 100
Value
42
Quality
57
FCF yld3.5%
Earn yld0.3%
EV/EBITDA15.4x
ROE3.4%
Gross mgn78%
Net mgn1.7%
Debt/EBITDA1.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
61,936 shares@ SEK 235.150.0090% mcap24.1% of flowAktieISINISIN SE0000872095FI:csv-c581b4c1a89c672b00d4
25 of 69 declarations
About Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ) is a Swedish pharmaceutical company focused on developing treatments for rare diseases. It is listed on the Stockholm Stock Exchange under the symbol XSTO.